Perth-based NeuroScientific Biopharmaceuticals has appointed leading Australian clinical research organisation (CRO) Southern Star Research to manage its planned phase two clinical trial for refractory Crohn’s disease in Australia and the United States.
asserted
Biopharmaceuticals → base → Australia
The appointment is a key operational milestone in the company’s push to evaluate its patented “StemSmart” stem cell technology, with trials slated to start by the end of the year.
asserted
trials → evaluate → year
Refractory Crohn’s disease and, in particular, fistulising Crohn’s, where ulcerations can develop into abnormal tunnels connecting the bowel with other organs or the skin, are both notoriously difficult to treat.
asserted
ulcerations → fistulise → organs
Neuroscientific’s innovative StemSmart therapy uses a specialised class of mesenchymal stem cells (MSC’s), prepared as a simple intravenous infusion.
asserted
therapy → use → infusion
These cells are harvested from adult donor bone marrow and then run through a patented refinement process designed to dial up their therapeutic punch and improve clinical outcomes.
‘This appointment is a key operational milestone towards the initiation of the Phase 2 clinical trial by the end of CY2026.’NeuroScientific
asserted
appointment → harvest → end
Better still, mesenchymal stem cells are universal donor cells, meaning no donor-recipient matching and no waiting lists.
asserted
cells → mean → matching
In practical terms, StemSmart is shaping up as a genuine off-the-shelf cell therapy.
asserted
StemSmart → shape → therapy
Southern Star Research, one of Australia’s leading CRO’s, will be responsible for identifying, setting up and managing clinical sites for the trial, engaging with clinicians and principal investigators and coordinating the logistics of delivering NeuroScientific’s StemSmart product to enrolled patients.
asserted
Research → lead → patients
The company has a strong pedigree, having recently been named best CRO in Australia at the 2026 Asia-Pacific Bioprocessing Excellence Awards.
asserted
company → have → Awards
The move follows the company’s successful engagement with the all-powerful US Food & Drug Administration (FDA), where it held a crucial meeting in August to gain feedback on its planned trial.
asserted
it → follow → trial
Today’s appointment of a CRO demonstrates the company is now executing on its stated plan to enter the lucrative US market.
asserted
company → demonstrate → market
The appointment marks NeuroScientific’s next step into a significant and expanding field.
asserted
appointment → mark → field
The global market for Crohn’s disease therapies is already valued at around US$13 (A$18.7) billion and is forecast to see steady growth over the next decade, underlining the commercial relevance of new solutions.
asserted
market → value → solutions
Notably, stem cell programs for Crohn’s are gaining serious momentum, with multiple clinical trials underway globally, signalling sustained scientific and commercial interest in the space.
asserted
trials → gain → space
NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: “We are delighted to appoint Southern Star Research to deliver StemSmart to patients suffering from treatment-resistant Crohn’s disease.
asserted
We → say → disease
Southern Star Research’s capabilities are a strong fit for our program as we progress towards clinical site start-up and engagement with principal investigators.
asserted
we → progress → investigators
The company’s confidence to push into a major phase two study is underpinned by highly encouraging results from a previous Special Access Program (SAP) trial in fistulising Crohn’s.
asserted
confidence → push → Crohn
Importantly, all five patients in that study showed improvement following treatment, with no serious adverse events recorded, a strong outcome in a group typically resistant to conventional therapies.
asserted
events → show → therapies
The focus on Crohn’s disease represents a significant strategic pivot for NeuroScientific, which spent years developing its “EmtinB” peptide for neurodegenerative conditions such as Alzheimer’s disease.
asserted
which → represent → disease
However, after acquiring the StemSmart technology platform in mid-2025, the company rapidly reoriented its focus.
asserted
company → acquire → focus
The clinical need for new treatments for difficult-to-treat patient subsets remains high, a fact underscored by recent positive results from Johnson & Johnson in perianal fistulising Crohn’s disease, highlighting the considerable big-pharma firepower now being trained on the toughest end of the Crohn’s treatment spectrum.
asserted
need → treat → spectrum
With promising early data from its SAP trial, a clear regulatory pathway being forged with the FDA, and now a leading CRO on board, NeuroScientific appears to be ticking all the right boxes as it advances its StemSmart technology towards a pivotal international trial.
asserted
it → forge → trial
Is your ASX-listed company doing something interesting?
asserted
company → list → something
The Aporia
